ArticleActa oncologica (Stockholm, Sweden)2025
Dual-tracer autoradiographic analysis of glucose metabolism and hypoxia in orthotopic and PDX tumor models.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeQuantification/mapping of tumor hypoxia may guide pretreatment decision-making in radiation oncology. Hypoxia-selective positron emission tomography (PET) tracers, like 18F-fluoroazomycin arabinoside (FAZA), allow assessment of hypoxia, but since hypoxia stimulates glycolysis, fluorodeoxyglucose (FDG) and hypoxia-PET may provide overlapping/similar information. Clinical dual-tracer PET studies are highly complex and remain inconclusive. Accordingly, we developed dual-tracer autoradiography techniques to allow high-resolution assessment of the spatial coupling of FAZA and 14C-2DG (FDG-analogue), without the time-separation and co-registration-related inaccuracies intrinsic to PET. Patient/material and methods: Orthotopic lung adenocarcinomas were induced in CRISPR/Cas9 knock-in mice. Mammary adenocarcinomas developed spontaneously in transgenic mice overexpressing ErbB2 (Her2). Patient-derived-xenografts (PDX) were established in immunocompromised mice using biopsies from oropharyngeal cancer patients. Tumor growth was followed by MRI/Caliper measurements. Mice were administered with FAZA (~40 MBq)/14C-2DG (37 kBq)/pimonidazole and sacrificed. Tumor cryosections were analyzed for FAZA/14C-2DG using dual-tracer autoradiography followed by histological stainings. Complementary autoradiograms were co-registered and covered by a square-grid (0.5 × 0.5 mm), and Pearson correlation coefficients (R) were calculated. RESULTS/
interpretationHypoxic sub-volumes (FAZA/pimonidazole) were commonly present. A reasonable spatial overlap between FAZA and 14C-2DG was observed in most lung and oropharyngeal tumors with R typically exceeding 0.55. In the breast tumor model, the extent of overlap between FAZA and 14C-2DG varied widely with R ranging from 0.03 to 0.82, which may relate to intertumor mutational differences in this Her2+ oncogene-driven model. Our results suggest a putative role for FDG-PET to identify hypoxic foci and guide dose-escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.